Skip to main content
. Author manuscript; available in PMC: 2010 Feb 10.
Published in final edited form as: Mutat Res. 2008 Nov 12;661(1-2):47. doi: 10.1016/j.mrfmmm.2008.11.001

Table 3.

Mutagenicity, DNA adducts, and abasic sites induced by compounds in strain TA100 in liquid-suspension assay

Compound Concen.
(µg/ml)
Percent
survival
Rev/106
survivors
Fold
increasea
Stable adducts/
108 nucleotides
± S.Eb
Abasic sites/
105 nucleotides
± S.Ec
DMSO (0.025 ml/ml) 100 0.8 1.0 0.024 ± 0.000 5.9 ± 0.33
B[c]P 20 71 3.1 3.9 1.600 ± 0.040 3.3 ± 0.12
B[c]P 3,4-diol 2 56 10.7 10.7 5.900 ± 0.230 4.2 ± 0.16
5 20 18.7 23.4 4.500 ± 0.034 5.3 ± 0.27
P[3,4-b]T 10 24 4.3 5.3 0.090 ± 0.007 6.2 ± 0.26
P[3,4-b]T 8,9-diol 2 91 2.0 2.5 0.170 ± 0.045 2.9 ± 0.23
5 63 2.2 2.8 0.750 ± 0.045 4.7 ± 0.25
P[4,3-b]T 8,9-diol 5 47 4.9 6.1 0.650 ± 0.045 5.5 ± 0.16
P[3,4-b]T sulfone 10 56 14.1 17.6 Not detected 18.4 ± 0.64
20 37 49.1 62.1 Not detected 15.1 ± 0.43
a

Fold increase in mutant frequency relative to that of DMSO-treated cells.

b

Average and standard error are based on two subsamples from a single biological sample for each compound. These standard errors represent technical measurement error only and should not be used to assess differences among compounds.

c

Average and standard error are based on triplicate measurements on each of three subsamples from a single biological sample for each compound. These standard errors represent technical measurement error only and should not be used to assess differences among compounds.